Related Experiment Video
Updated: Dec 29, 2025

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
Published on: August 8, 2025
Acute Coronary Syndrome Following Transcatheter Aortic Valve Replacement
Laurent Faroux1, Erika Munoz-Garcia2, Vicenç Serra3
1Quebec Heart and Lung Institute, Laval University, Canada (L.F., D.d.V., T.C., J.R.-C.).
Insights
Acute coronary syndrome after transcatheter aortic valve replacement (TAVR) is linked to poor outcomes. Revascularization improves survival, while STEMI increases mortality risk in TAVR patients.
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiovascular Research
Background:
- Limited data exists on coronary events post-transcatheter aortic valve replacement (TAVR).
- No prior studies have identified factors associated with adverse outcomes following TAVR-related acute coronary syndrome (ACS).
Purpose of the Study:
- To investigate the clinical characteristics of ACS events in TAVR patients.
- To determine the outcomes and prognostic factors associated with ACS following TAVR.
Main Methods:
- A multicenter cohort study of 270 patients experiencing ACS post-TAVR.
- Data collected included ACS presentation, procedural strategies, and clinical outcomes such as death, myocardial infarction, stroke, and major adverse cardiovascular or cerebrovascular events.
Main Results:
- ACS presentations varied, with non-ST-segment-elevation myocardial infarction (STEMI) type 2 being most common (31.9%).
- In-hospital mortality was 10.0%, and at median follow-up, overall mortality reached 43.0%.
- Revascularization at ACS diagnosis reduced all-cause death risk (HR, 0.54), while STEMI increased mortality risk (HR, 2.06).
Conclusions:
- ACS events in TAVR recipients have distinct characteristics and are associated with high mortality.
- STEMI and lack of revascularization are significant risk factors for adverse outcomes.
- Findings emphasize the need for improved prevention and management strategies for ACS post-TAVR.
Background:
Scarce data exist on coronary events following transcatheter aortic valve replacement (TAVR), and no study has determined the factors associated with poorer outcomes in this setting. This study sought to determine the clinical characteristics, outcomes, and prognostic factors of acute coronary syndrome (ACS) events following TAVR.
Methods:
Multicenter cohort study including a total of 270 patients presenting an ACS after a median time of 12 (interquartile range, 5-17) months post-TAVR. Post-ACS death, myocardial infarction, stroke, and overall major adverse cardiovascular or cerebrovascular events were recorded.
Results:
The ACS clinical presentation consisted of non-ST-segment-elevation myocardial infarction (STEMI) type 2 (31.9%), non-STEMI type 1 (31.5%), unstable angina (28.5%), and STEMI (8.1%). An invasive strategy was used in 163 patients (60.4%), and a percutaneous coronary intervention was performed in 97 patients (35.9%). Coronary access issues were observed in 2.5% and 2.1% of coronary angiography and percutaneous coronary intervention procedures, respectively. The in-hospital mortality rate was 10.0%, and at a median follow-up of 17 (interquartile range, 5-32) months, the rates of death, stroke, myocardial infarction, and major adverse cardiovascular or cerebrovascular events were 43.0%, 4.1%, 15.2%, and 52.6%, respectively. By multivariable analysis, revascularization at ACS time was associated with a reduction of the risk of all-cause death (hazard ratio, 0.54 [95% CI, 0.36-0.81] P=0.003), whereas STEMI increased the risk of all-cause death (hazard ratio, 2.06 [95% CI, 1.05-4.03] P=0.036) and major adverse cardiovascular or cerebrovascular events (hazard ratio, 1.97 [95% CI, 1.08-3.57] P=0.026).
Conclusions:
ACS events in TAVR recipients exhibited specific characteristics (ACS presentation, low use of invasive procedures, coronary access issues) and were associated with a poor prognosis, with a very high in-hospital and late death rate. STEMI and the lack of coronary revascularization determined an increased risk. These results should inform future studies to improve both the prevention and management of ACS post-TAVR.
Related Concept Videos
Acute Coronary Syndrome I: Introduction
Aortic Regurgitation III: Medical Management
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome IV: Interprofessional Care
Aortic Regurgitation I: Introduction

